How Did GeneDx (NASDAQ:WGS) Exome and Genome Volume Grow 25% in Q3 2026?

Sonal Goyal

10 November 2026 06:56 PM AEDT

How Did GeneDx (NASDAQ:WGS) Exome and Genome Volume Grow 25% in Q3 2026?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Revenue was $123.1 million in the third quarter of 2026, up 5% year over year.
Exome and genome test Revenue was $110.4 million, up 12%.
Exome and genome test result Volume was 32,134, up 25% year over year.
Full-year 2026 revenue guidance of $475 million to $490 million was reiterated.

GeneDx (NASDAQ:WGS) reported third-quarter 2026 revenue of $123.1 million, an increase of 5% year over year. Exome and genome test revenue was $110.4 million, up 12%. Exome and genome test result volume reached 32,134, an increase of 25% year over year, and the company reiterated its full-year 2026 revenue guidance of $475 million to $490 million.

Revenue and Test Volume

Revenue grew 5% year over year to $123.1 million. Exome and genome test revenue grew 12% to $110.4 million. The company reported exome and genome accession growth of 28% year over year, with test result volume growing 25%.

Test result volume rose to 32,134 in the third quarter. The company's revenue from other test categories is included in its total revenue of $123.1 million.

Gross Margin and Adjusted Net Income

Adjusted gross margin was 72% in the third quarter of 2026. That compares with 70% in the second quarter of 2026 and 74% in the third quarter of 2025. GAAP gross margin for the quarter was 70%.

Adjusted Net Income was $8.6 million for the quarter. Adjusted net income is a non-GAAP measure that the company reconciles to GAAP results in its financial tables.

2026 Guidance

The company reiterated its full-year 2026 revenue guidance of $475 million to $490 million. The guidance was stated alongside the third-quarter results in the company's report.

The company's third-quarter results and guidance are reported as of November 9, 2026.

Final Word

GeneDx reported third-quarter 2026 revenue of $123.1 million, exome and genome test revenue of $110.4 million, exome and genome test result volume of 32,134, adjusted gross margin of 72%, adjusted net income of $8.6 million and reiterated full-year 2026 revenue guidance of $475 million to $490 million.

FAQs

Q: What was GeneDx's third-quarter 2026 revenue?

A: Revenue was $123.1 million, up 5% year over year.

Q: How much did exome and genome test volume grow?

A: Exome and genome test result volume was 32,134, up 25% year over year.

Q: What was adjusted gross margin?

A: Adjusted gross margin was 72% in the third quarter of 2026.

Q: What full-year guidance did the company reiterate?

A: The company reiterated full-year 2026 revenue guidance of $475 million to $490 million.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.